Heparin calcium is a generic injectable anticoagulant medication commonly used in cardiac bypass surgery and haemodialysis procedures. It is also used in the treatment of pulmonary embolism and deep vein thrombosis. The increasing cases of heart attacks, strokes and other cardiovascular diseases has led to a rise in the demand for anticoagulants like heparin calcium.

The global Heparin Calcium Market is estimated to be valued at US$ 1407.91 Mn in 2023 and is expected to exhibit a CAGR of 2.7% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics

The heparin calcium market is primarily driven by the rising prevalence of cardiovascular diseases. Cardiovascular diseases are the leading cause of death globally and account for over 17 million deaths each year according to the World Health Organization. According to the Heart and Stroke Foundation of Canada, around 40% of Canadian adults are living with some form of cardiovascular disease. An ageing population as well as risk factors like obesity, physical inactivity and smoking are contributing to this rise in cardiovascular diseases. Additionally, increasing surgical procedures that require anticoagulation therapy and growing awareness about deep vein thrombosis are also expected to boost the demand for heparin calcium products over the forecast period. However, the risk of bleeding associated with heparin therapy along with the availability of alternative oral anticoagulants are some of the factors that may limit the growth of this market.

SWOT Analysis

Strength: Heparin calcium is a widely used anticoagulant in surgical procedures and for treating thrombosis or deep vein thrombosis. Its use is well established in medical practice. With its high bioavailability and predictable anticoagulant response, heparin calcium is preferred over other anticoagulants. Availability of generic heparin calcium also makes it a relatively affordable treatment option.

Weakness: Heparin calcium has a narrow therapeutic window. This means that patients receiving heparin calcium need regular monitoring to ensure optimal anticoagulation and avoid major bleeding complications due to over-anticoagulation. There is also a risk of osteoporosis and thrombocytopenia with long term use of heparin calcium.

Opportunity: Growing geriatric population susceptible to coagulation disorders like thrombosis and atrial fibrillation presents an opportunity for increased uptake of heparin calcium. Emergence of newer oral anticoagulants have expanded the available treatment options but heparin calcium still remains a mainstay, especially for injectable therapies in hospital settings. Increased awareness about prevention and treatment of coagulation disorders can boost demand.

Threats: Stringent regulations pertaining to production and distribution of heparin calcium pose challenges for manufacturers. Newer oral anticoagulants threaten the market share of heparin calcium due to advantages of oral administration over injections. Price controls and reimbursement policies across countries can impact adoption of heparin calcium therapy.

Key Takeaways

The global Heparin Calcium Market Size is expected to witness moderate growth over the forecast period of 2023 to 2030 supported by increased prevalence of thrombosis, atherosclerosis and rising aging population globally. The regional analysis indicates that developed markets like North America and Europe currently dominate the heparin calcium market owing to presence of sophisticated healthcare systems and widespread medical coverage. However, Asia Pacific region is projected to witness the highest growth on account of rising incidence of cardiovascular diseases, improving access to healthcare facilities in developing countries and increasing focus of leading manufacturers on emerging markets.

Key players operating in the heparin calcium market are Sanofi, Pfizer Inc., Dongying Tiandong Pharmaceutical Co., Ltd., PANPHARMA S.A., Merck KGaA, Teva Pharmaceutical Industries Ltd., SMITHFIELD BIOSCIENCE, Afine Chemicals Limited, Yino Pharma Limited, Shandong Sheelian Pharmaceutical Co., Ltd., Aspen Holdings, Opocrin S.p.A. The market leader Sanofi leads with its heparin calcium injection formulation marketed under the brand name Lovenox. Other prominent players are focusing on expanding in Asia Pacific and Latin America through collaborations and licensing agreements with regional pharma companies.

Get More Insights On This Topic: https://blogger-veritas.blogspot.com/2023/12/heparin-calcium-growth-accelerated-by.html